Abstract
BackgroundThe aim of this study is to evaluate the impact of diabetes, hypertension, cardiovascular disease and the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) with severity (invasive mechanical ventilation or intensive care unit admission or O2 saturation < 90%) and mortality of COVID-19 cases.MethodsSystematic review of the PubMed, Cochrane Library and SciELO databases was performed to identify relevant articles published from December 2019 to 6th May 2020. Forty articles were included involving 18.012 COVID-19 patients.ResultsThe random-effect meta-analysis showed that diabetes mellitus and hypertension were moderately associated respectively with severity and mortality for COVID-19: Diabetes [OR 2.35 95% CI 1.80–3.06 and OR 2.50 95% CI 1.74–3.59] Hypertension: [OR 2.98 95% CI 2.37–3.75 and OR 2.88 (2.22–3.74)]. Cardiovascular disease was strongly associated with both severity and mortality, respectively [OR 4.02 (2.76–5.86) and OR 6.34 (3.71–10.84)]. On the contrary, the use of ACEI/ARB, was not associate with severity of COVID-19.ConclusionIn conclusion, diabetes, hypertension and especially cardiovascular disease, are important risk factors for severity and mortality in COVID-19 infected people and are targets that must be intensively addressed in the management of this infection.
Highlights
The World Health Organization declared the SARSCoV-2 outbreak, the Coronavirus Disease–COVID-19, as pandemic on 11th of March of 2020
Current studies and reviews have helped to clarify the clinical profile of COVID-19 [4], regarding to the most prominent symptoms, as well as to factors associated with greater susceptibility to infection and severity of the disease
The aim of this study is to evaluate the association of diabetes, hypertension, cardiovascular disease and ACE inhibitors (ACEI)/ angiotensin II receptor blocker (ARB) exposure with severity–intensive care unit treatment or mechanical ventilation necessity or O2 saturation < 90%–or mortality from COVID-19 infection
Summary
The World Health Organization declared the SARSCoV-2 outbreak, the Coronavirus Disease–COVID-19, as pandemic on 11th of March of 2020. At that time, it affected 114 different countries, being responsible for about 4 thousand deaths around the world. Current studies and reviews have helped to clarify the clinical profile of COVID-19 [4], regarding to the most prominent symptoms, as well as to factors associated with greater susceptibility to infection and severity of the disease. The aim of this study is to evaluate the impact of diabetes, hypertension, cardiovascular disease and the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) with severity (inva‐ sive mechanical ventilation or intensive care unit admission or O2 saturation < 90%) and mortality of COVID-19 cases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have